Sign in to view content

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy

Jeffrey S. Heier, MD

Video
Published 2022

Related

Episode 13: Long-Term Treatment of Wet AMD by 50+ Anti-VEGF Injections with Dr. Sean Adrean
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics
David R Lally, MD
Annual Meeting Talks
2021
Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017

Category: AMD-Non-Neovascular

See more